National Center for Rehabilitative Auditory Research (NCRAR)
International Ototoxicity Management Group (IOMG)The International Ototoxicity Management Working Group (IOMG) is a global consortium of international stakeholders from universities, task forces, health foundations, professional societies, government agencies and patients created to address healthcare gaps in the clinical management of individuals who experience hearing loss, tinnitus, and/or balance difficulties following medical, occupational or environmental exposures to ototoxicants. Ototoxicity management includes the diagnosis, monitoring, rehabilitation and/or therapeutic treatment of these cases. Despite the well-established physical, socio-economic, and psychological consequences of hearing and balance dysfunction, clinical practice in these situations is not consistent within or across countries. Few healthcare delivery models integrate ototoxicity management into the essential and/or life-preserving care pathways that utilize therapies that unavoidably increase the risk of ototoxicity. Additionally, there are no standard methods for the auditory surveillance of individuals exposed to hazardous chemicals at work. Consensus guidelines and tools for implementation and health promotion are needed to proactively manage ototoxicity from medical, environmental and occupational exposures. The IOMG will enhance the social participation and quality of life of millions of individuals worldwide by addressing healthcare gaps and promoting ototoxicity management that will give patients and workers greater control over their long-term auditory and vestibular health.
Our long-term goal is to develop a comprehensive set of guidelines and/or position statements, implementation and health promotion tool kits that will address ototoxicity management gaps in relation to best practices. Our approach is to harmonize consensus opinion from international experts with the priorities of patients and the specific organizations that govern have the power to influence patients’ ototoxic exposures. To reach this goal, near-term objectives are to establish best practices for widespread implementation of ototoxicity management in specific clinical environments (e.g., medical oncology, pulmonology, otology, audiology, cystic fibrosis and infectious disease clinics), healthcare structures (community-based, government, third party payer), and regional economies (emerging, transitional, strong). Guided by an international team of patients, clinicians, researchers, and policy makers the group plans to disseminate ototoxicity management materials and toolkits in traditional and non-traditional formats to accommodate specific work environments, healthcare structures, healthcare workers, and patients across the globe.
IOMG links:IOMG member roster
IOMG leadership and organization, including subgroups and focus areas
IOMG News and Updates:New! - click here for information about **February 16, 2021** seminar
- New! Click here for "Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort" AJA, 2021 Jan 19;1-20. doi: 10.1044/2020_AJA-20-00059
- Click here for "Cost-effectiveness of implementing routine hearing screening using a tablet audiometer for pediatric cystic fibrosis patients receiving high-dose IV aminoglycosides" JMCP, Volume 27 Issue (2) Huang, McKinzie, Tak
- Click here for "An Ototoxicity Grading System Within a Mobile App (OtoCalc) for a Resource-Limited Setting to Guide Grading and Management of Drug-Induced Hearing Loss in Patients With Drug-Resistant Tuberculosis: Prospective, Cross-Sectional Case Series" (Monitoring Editor: Gunther Eysenbach)
- Click here for "Exposure to lead, mercury, styrene, and toluene and hearing impairment: Evaluation of dose-response relationships, regulations, and controls" (by Ehsan Hemmativaghef)